RDi USA Inc. Launches at ADLM 2026, Bringing Automated Diagnostic Kitting and Connected Self-Sampling Pathways to the U.S.
New U.S. business combines automated diagnostic kit manufacturing, fulfillment, logistics and digital pathway
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
RDi today announced the launch of RDi USA Inc. at the ADLM 2026 Clinical Lab Expo, where the new U.S. business will make its official industry debut at Booth #4454 from July 28–30.
RDi USA has been created to help laboratories, diagnostic manufacturers, healthcare providers, screening organizations and research partners overcome one of the largest barriers to scaling diagnostic testing: the fragmented infrastructure surrounding the test itself, for partners operating across complex and high-volume testing environments.
The company brings together kit design, component sourcing, automated assembly, fulfillment, sample-return logistics, laboratory integration and digital engagement within one connected operating model.
RDi USA enters the market with proven experience from across the RDi Group. More than 130 million self-collection kits have been delivered, 163 self-sample collection kit designs registered and over one billion patient data records processed. RDi’s automated production lines can manufacture hundreds of thousands of kits each day, using camera-led validation and inspection to check every unit and reduce the risks associated with manual assembly.
RDi is also establishing U.S.-based manufacturing and fulfillment capacity, supported by more than two decades of experience delivering high-volume screening and diagnostic programs.
David Cahill, Group Chief Executive Officer of RDi, said:
“Too many diagnostic programs are still held back by disconnected suppliers, manual processes and limited visibility. RDi USA has been created to remove that friction.
“We are not simply bringing another kitting supplier into the market. We are bringing an operating model that connects automated manufacturing, fulfillment, logistics, digital technology and laboratory integration into one dependable pathway.
“The next phase of testing will increasingly happen beyond traditional clinical settings—in people’s homes, workplaces, pharmacies and communities. Our role is to give laboratories and healthcare partners the infrastructure they need to make that transition safely, efficiently and at American scale.”
RDi supports population screening, pathology, clinical trials, retail and pharmacy testing, occupational health, health insurance, wellness and genetics, and direct-to-consumer services. Its +CURA digital pathway platform can support patients from test ordering and activation through sample collection, return, laboratory processing and access to results.
Visitors to ADLM 2026 can meet the RDi USA leadership team and explore its diagnostic kitting and connected pathway capabilities at Booth 4454 in the Anaheim Convention Center.
To arrange a meeting at ADLM or discuss a U.S. diagnostic program, visit www.thisisrdi.com or email usa@thisisrdi.com.
About RDi
RDi designs, builds and operates end-to-end diagnostic and healthcare pathways. The company combines specimen-collection kit design, automated manufacturing, fulfillment, logistics, digital engagement and laboratory integration to help healthcare organizations make testing more accessible, dependable and scalable.
For more than two decades, RDi has supported screening, pathology, self-sampling, clinical research and at-home testing programs in the United Kingdom and international markets.
RDi’s purpose is simple: Better healthcare, made possible.
More information is available at www.thisisrdi.com.
ADLM 2026 | Anaheim Convention Center | Clinical Lab Expo: July 28–30, 2026 | Booth 4454 | #ADLM2026 | #RDiUSA
View source version on businesswire.com: https://www.businesswire.com/news/home/20260729631095/en/
Media gallery
